Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Closing Price
Day's Change
0.0098 (1.21%)
B/A Size
Day's High
Day's Low

10-day average volume:

Fortinet stock sinks after earnings as billings forecast underwhelms

5:16 pm ET November 2, 2022 (MarketWatch)

Shares of Fortinet Inc. were off more than 13% in after-hours trading Wednesday after the cybersecurity company topped expectations with its latest earnings and revenue numbers but delivered a billings forecast for the current period that came up light. The company logged third-quarter net income of $231.6 million, or 29 cents a share, up from $163.1 million, or 19 cents a share, in the year-earlier period. After adjusting for stock-based compensation and certain other items, Fortinet earned 33 cents a share, up from 20 cents a share a year before, while analysts tracked by FactSet had been anticipating 27 cents a share. Revenue rose to $1.15 billion from $867 million, whereas the FactSet consensus was for $1.12 billion. For the fourth quarter, Fortinet executives anticipate $1.275 billion to $1.315 billion in revenue, along with 38 cents to 40 cents in adjusted earnings per share. The FactSet consensus was for $1.274 billion and 35 cents, respectively. Executives also gave a forecast for $1.665 billion to $1.720 billion in billings, while the FactSet consensus was for $1.740 billion. Fortinet's billings metric reflects other business signed during the quarter that was not recognized as revenue.

-Emily Bary


(END) Dow Jones Newswires

November 02, 2022 17:16 ET (21:16 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.